Vikas Gupta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3075078/publications.pdf

Version: 2024-02-01

224	13,751	28242 55	23514 111
papers	citations	h-index	g-index

225	225	225	12185
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. New England Journal of Medicine, 2012, 366, 799-807.	13.9	1,738
2	Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature, 2014, 506, 328-333.	13.7	1,241
3	Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood, 2012, 119, 296-307.	0.6	559
4	Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome. Journal of Clinical Oncology, 2010, 28, 1878-1887.	0.8	459
5	Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure. Journal of Clinical Oncology, 2010, 28, 3730-3738.	0.8	386
6	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. Journal of Hematology and Oncology, 2017, 10, 55.	6.9	302
7	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis. JAMA Oncology, 2018, 4, 652.	3.4	261
8	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica, 2015, 100, 479-488.	1.7	246
9	Outcome of Transplantation for Myelofibrosis. Biology of Blood and Marrow Transplantation, 2010, 16, 358-367.	2.0	245
10	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood, 2014, 124, 2596-2606.	0.6	228
11	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2018, 5, e73-e81.	2.2	211
12	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. Journal of Hematology and Oncology, 2017, 10, 156.	6.9	210
13	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica, 2015, 100, 1139-1145.	1.7	203
14	A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies. Clinical Cancer Research, 2008, 14, 8295-8301.	3.2	183
15	The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia in first and second complete remission. Blood, 2010, 116, 366-374.	0.6	178
16	Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?. Journal of Clinical Oncology, 2011, 29, 805-813.	0.8	178
17	Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Oncology, 2013, 31, 1285-1292.	0.8	171
18	Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood, 2010, 116, 1839-1848.	0.6	168

#	Article	IF	Citations
19	Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood, 2011, 117, 2307-2318.	0.6	161
20	Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigenâ€“Identical Sibling Transplants for Adults With Leukemia. Journal of Clinical Oncology, 2008, 26, 5728-5734.	0.8	159
21	Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood, 2011, 118, 2351-2357.	0.6	148
22	The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood, 2009, 113, 3110-3118.	0.6	147
23	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood, 2009, 113, 5074-5082.	0.6	143
24	Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica, 2013, 98, 1865-1871.	1.7	143
25	Treatment of adults with BCRâ€ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. British Journal of Haematology, 2009, 146, 76-85.	1.2	137
26	Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica, 2010, 95, 2119-2125.	1.7	137
27	MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood, 2014, 124, 1183-1191.	0.6	135
28	Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2014, 20, 89-97.	2.0	130
29	Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica, 2016, 101, 1065-1073.	1.7	130
30	Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood, 2008, 112, 3500-3507.	0.6	127
31	Outcomes of Allogeneic Hematopoietic Cell Transplantation inÂPatients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biology of Blood and Marrow Transplantation, 2016, 22, 432-440.	2.0	127
32	Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood, 2013, 121, 339-350.	0.6	123
33	Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood, 2013, 121, 2725-2733.	0.6	119
34	Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2009, 15, 109-117.	2.0	98
35	Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood, 2012, 120, 1367-1379.	0.6	95
36	Disease biology rather than age is the most important determinant of survival of patients â‰¥ 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer, 2005, 103, 2082-2090.	2.0	87

#	Article	IF	Citations
37	Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica, 2017, 102, 327-335.	1.7	87
38	The clinical benefit of ruxolitinib across patient subgroups: analysis of a placeboâ€controlled, Phase <scp>III</scp> study in patients with myelofibrosis. British Journal of Haematology, 2013, 161, 508-516.	1.2	83
39	Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center forÂInternational Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2012, 18, 280-288.	2.0	81
40	Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood, 2008, 112, 426-434.	0.6	80
41	Second Unrelated Donor Hematopoietic Cell Transplantation for Primary Graft Failure. Biology of Blood and Marrow Transplantation, 2010, 16, 1099-1106.	2.0	80
42	A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica, 2017, 102, 94-102.	1.7	80
43	Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. American Journal of Hematology, 2014, 89, 363-368.	2.0	79
44	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Advances, 2020, 4, 4282-4291.	2.5	77
45	Similar Outcomes of Cryopreserved Allogeneic Peripheral Stem Cell Transplants (PBSCT) Compared to Fresh Allografts. Biology of Blood and Marrow Transplantation, 2007, 13, 1233-1243.	2.0	69
46	Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older. Biology of Blood and Marrow Transplantation, 2005, 11, 764-772.	2.0	67
47	Prior rituximab correlates with less acute graftâ€versusâ€host disease and better survival in Bâ€cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. British Journal of Haematology, 2009, 145, 816-824.	1.2	66
48	Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults. British Journal of Haematology, 2006, 134, 95-99.	1.2	64
49	Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myelogenous Leukemia (AML) in Adults. Biology of Blood and Marrow Transplantation, 2010, 16, 1442-1450.	2.0	64
50	Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and singleâ€lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. British Journal of Haematology, 2010, 148, 791-796.	1.2	63
51	Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 214-221.e1.	0.2	63
52	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	2.5	63
53	The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults. Critical Reviews in Oncology/Hematology, 2007, 64, 19-30.	2.0	62
54	Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age. Journal of Geriatric Oncology, 2015, 6, 262-271.	0.5	62

#	Article	IF	Citations
55	Primary analysis of JUMP, a phase 3b, expandedâ€access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. British Journal of Haematology, 2020, 189, 888-903.	1.2	61
56	Comparison of Outcomes after Transplantation of G-CSFâ€“Stimulated Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-Matched Sibling Donors for Patients with Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2011, 17, 1018-1024.	2.0	60
57	Allogeneic Hematopoietic Cell Transplantation in Human Immunodeficiency Virusâ€“Positive Patients with Hematologic Disorders: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2009, 15, 864-871.	2.0	58
58	One-Antigen Mismatched Related versus HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Adults with Acute Leukemia: Center for International Blood and Marrow Transplant Research Results in the Era of Molecular HLA Typing. Biology of Blood and Marrow Transplantation, 2011, 17, 640-648.	2.0	55
59	The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica, 2016, 101, 1426-1433.	1.7	53
60	Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research. Haematologica, 2013, 98, 185-192.	1.7	50
61	The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica, 2016, 101, e482-e484.	1.7	50
62	Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia. Critical Reviews in Oncology/Hematology, 2009, 69, 168-174.	2.0	49
63	Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. Blood Advances, 2017, 1, 1729-1738.	2.5	48
64	Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. Biology of Blood and Marrow Transplantation, 2019, 25, 1142-1151.	2.0	48
65	Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biology of Blood and Marrow Transplantation, 2004, 10, 867-876.	2.0	47
66	Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood, 2012, 119, 4083-4090.	0.6	47
67	The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. Blood Advances, 2018, 2, 2658-2671.	2.5	47
68	Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biology of Blood and Marrow Transplantation, 2019, 25, 256-264.	2.0	47
69	Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. OncoTargets and Therapy, 2013, 7, 13.	1.0	46
70	A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. Cancer Medicine, 2016, 5, 3031-3040.	1.3	46
71	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. Biology of Blood and Marrow Transplantation, 2016, 22, 932-940.	2.0	43
72	MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. Blood, 2019, 134, 670-670.	0.6	42

#	Article	IF	Citations
73	Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10â€Color flow cytometry diagnosis and HyperCVAD therapy. American Journal of Hematology, 2016, 91, 283-286.	2.0	40
74	Validation of National Institutes of Health Global Scoring System for Chronic Graft-Versus-Host Disease (GVHD) According to Overall and GVHD-Specific Survival. Biology of Blood and Marrow Transplantation, 2014, 20, 556-563.	2.0	38
75	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica, 2014, 99, 292-298.	1.7	38
76	Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2010, 16, 543-547.	2.0	37
77	A third course of anti-thymocyte globulin in aplastic anaemia is only beneficial in previous responders. British Journal of Haematology, 2005, 129, 110-117.	1.2	36
78	Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Expert Opinion on Pharmacotherapy, 2012, 13, 2397-2407.	0.9	36
79	Influence of FLT3â€internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediateâ€risk karyotype acute myeloid leukemia. Cancer, 2012, 118, 6110-6117.	2.0	36
80	A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis. British Journal of Haematology, 2015, 168, 384-394.	1.2	36
81	Hematopoietic Cell Transplantation as Curative Therapy forÂPatients with Myelofibrosis: Long-Term Success in all AgeÂGroups. Biology of Blood and Marrow Transplantation, 2015, 21, 1883-1887.	2.0	36
82	Myelofibrosis: to transplant or not to transplant?. Hematology American Society of Hematology Education Program, 2016, 2016, 543-551.	0.9	36
83	Incidence and Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1589-1599.	2.0	34
84	A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 2793-2802.	0.6	33
85	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 248-257.	2.0	33
86	Critical illness in patients with hematologic malignancy: a population-based cohort study. Intensive Care Medicine, 2021, 47, 1104-1114.	3.9	32
87	A Prospective Study Comparing the Outcomes and Health-Related Quality of Life in Adult Patients with Myeloid Malignancies Undergoing Allogeneic Transplantation Using Myeloablative or Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2012, 18, 113-124.	2.0	31
88	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncology, 2021, 17, 1449-1458.	1.1	31
89	Late Effects in Hematopoietic Cell Transplant Recipients with Acquired Severe Aplastic Anemia: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2012, 18, 1776-1784.	2.0	30
90	Laboratory Investigation of Myeloproliferative Neoplasms (MPNs). American Journal of Clinical Pathology, 2016, 146, 408-422.	0.4	30

#	Article	IF	Citations
91	Outcomes of older patients (â‰¥60â€ƒyears) with acquired aplastic anaemia treated with immunosuppressive therapy. British Journal of Haematology, 2008, 143, 738-743.	1.2	29
92	Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABLâ€“negative MPN in blast phase. Blood Advances, 2020, 4, 5562-5573.	2.5	28
93	Clinical efficacy of prophylactic strategy of longâ€term lowâ€dose acyclovir for Varicellaâ€Zoster virus infection after allogeneic peripheral blood stem cell transplantation*. Clinical Transplantation, 2008, 22, 770-779.	0.8	27
94	Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatricâ€based protocol. British Journal of Haematology, 2013, 163, 458-464.	1.2	27
95	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Advances, 2021, 5, 975-983.	2.5	27
96	Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2011, 17, 124-132.	2.0	26
97	Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia, 2022, 36, 856-864.	3.3	26
98	Childhood Obesity and Outcomes after Bone Marrow Transplantation for Patients with Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2011, 17, 737-744.	2.0	25
99	Peripheral Blood Eosinophilia Has a Favorable Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 471-482.	2.0	24
100	Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer, 2022, 128, 2420-2432.	2.0	24
101	Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy. American Journal of Hematology, 2008, 83, 54-58.	2.0	23
102	The Effect of Smoking on Allogeneic Transplant Outcomes. Biology of Blood and Marrow Transplantation, 2009, 15, 1277-1287.	2.0	23
103	Treatment of Philadelphia chromosomeâ€positive acute lymphoblastic leukaemia with imatinib combined with a paediatricâ€based protocol. British Journal of Haematology, 2012, 158, 506-514.	1.2	23
104	A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia. Investigational New Drugs, 2016, 34, 614-624.	1.2	23
105	Prognostic significance of trisomy 4 as the sole cytogenetic abnormality in acute myeloid leukemia. Leukemia Research, 2003, 27, 983-991.	0.4	22
106	Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. Cancer, 2008, 112, 1513-1521.	2.0	22
107	Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2008, 14, 775-782.	2.0	22
108	Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia. Biology of Blood and Marrow Transplantation, 2012, 18, 1446-1454.	2.0	22

#	Article	IF	Citations
109	Social Media and Myeloproliferative Neoplasms (MPN)â€"Focus on Twitter and the Development of a Disease-specific Community: #MPNSM. Current Hematologic Malignancy Reports, 2015, 10, 413-420.	1.2	22
110	Clinical Features of Patients With Philadelphia-Negative Myeloproliferative Neoplasms Complicated by Portal Hypertension. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e1-e5.	0.2	22
111	A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 87-92.	0.2	21
112	Benefit of Allogeneic Transplantation in Patients Age â‰¥ 60ÂYears with Acute Myeloid Leukemia Is Limited to Those in First Complete Remission at Time of Transplant. Biology of Blood and Marrow Transplantation, 2014, 20, 474-479.	2.0	21
113	Early lymphocyte recovery at 28Âd postâ€transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts. European Journal of Haematology, 2014, 93, 273-280.	1.1	21
114	Impaired T Cell Responsiveness to Interleukin-6 in Hematological Patients with Invasive Aspergillosis. PLoS ONE, 2015, 10, e0123171.	1.1	21
115	Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment NaÃ¯ve Myelofibrosis Patients. Blood, 2019, 134, 4164-4164.	0.6	21
116	Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I. Blood, 2013, 122, 396-396.	0.6	21
117	Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia. Leukemia and Lymphoma, 2010, 51, 61-65.	0.6	20
118	Multiple Single-Nucleotide Polymorphismâ€"Based Risk Model for Clinical Outcomes After Allogeneic Stem-Cell Transplantation, Especially for Acute Graft-Versus-Host Disease. Transplantation, 2012, 94, 1250-1257.	0.5	19
119	Clinical Utility of Nextâ€generation Sequencing in the Management of Myeloproliferative Neoplasms: A Singleâ€Center Experience. HemaSphere, 2018, 2, e44.	1.2	19
120	Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. Leukemia and Lymphoma, 2021, 62, 918-926.	0.6	19
121	Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I. Blood, 2012, 120, 800-800.	0.6	19
122	Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis. Biology of Blood and Marrow Transplantation, 2014, 20, 1274-1281.	2.0	18
123	Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia. American Journal of Hematology, 2012, 87, 323-326.	2.0	17
124	Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research. Biology of Blood and Marrow Transplantation, 2013, 19, 1102-1108.	2.0	17
125	Mycophenolateâ€based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablativeâ€related donor stem cell transplantation. American Journal of Hematology, 2015, 90, 392-399.	2.0	17
126	Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 2270-2275.	2.0	17

#	Article	IF	Citations
127	Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability. Biology of Blood and Marrow Transplantation, 2019, 25, 1158-1163.	2.0	17
128	Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group. JCO Oncology Practice, 2020, 16, 351-359.	1.4	17
129	An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. Blood, 2011, 118, 3849-3849.	0.6	16
130	Incidence, Risk Factors, and Long-Term Outcomes of Sclerotic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1751-1757.	2.0	15
131	Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginaseâ€based therapy. British Journal of Haematology, 2020, 191, 748-754.	1.2	15
132	Allogeneic Peripheral Blood Stem Cell TransplantationÂSignificantly Increases Risk of Chronic Graft-versus-Host Disease of Lung Compared with Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1905-1910.	2.0	14
133	How we manage <scp>JAK</scp> inhibition in allogeneic transplantation for myelofibrosis. European Journal of Haematology, 2015, 94, 115-119.	1.1	14
134	Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for I nternational B lood and M arrow T ransplant R esearch cohort analysis. Cancer, 2017, 123, 2035-2042.	2.0	14
135	Comparison of outcomes of HCT in blast phase of BCR-ABL1â˜ MPN with de novo AML and with AML following MDS. Blood Advances, 2020, 4, 4748-4757.	2.5	14
136	Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I. Blood, 2011, 118, 278-278.	0.6	14
137	Cardiovascular Disease Among Patients With AML and CHIP-Related Mutations. JACC: CardioOncology, 2022, 4, 38-49.	1.7	14
138	Clinico-Biological Features and Prognostic Significance of PML/RARÎ± Isoforms in Adult Patients with Acute Promyelocytic Leukemia Treated with All Trans Retinoic Acid (ATRA) and Chemotherapy. Leukemia and Lymphoma, 2004, 45, 469-480.	0.6	13
139	Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL). Leukemia Research, 2005, 29, 113-114.	0.4	13
140	Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen. Leukemia Research, 2012, 36, 1517-1520.	0.4	13
141	Providing Personalized Prognostic Information for Adult Leukemia Survivors. Biology of Blood and Marrow Transplantation, 2013, 19, 1600-1607.	2.0	13
142	Outcomes of Hematopoietic Cell Transplantation in Adult Patients with Acquired Aplastic Anemia Using Intermediate-Dose Alemtuzumab-Based Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20, 1722-1728.	2.0	13
143	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1776-1782.	2.0	13
144	Investigational non-JAK inhibitors for chronic phase myelofibrosis. Expert Opinion on Investigational Drugs, 2020, 29, 461-474.	1.9	13

#	Article	IF	Citations
145	Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2). Blood, 2013, 122, 661-661.	0.6	13
146	Acute Lung Injury during Antithymocyte Globulin Therapy for Aplastic Anemia. Canadian Respiratory Journal, 2009, 16, e3-e5.	0.8	12
147	Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD. Annals of Hematology, 2017, 96, 805-815.	0.8	12
148	Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML. Blood Advances, 2019, 3, 2307-2311.	2.5	12
149	A Phase I Trial of Two Sequence-Specific Schedules of Decitabine and Vorinostat in Patients with Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 908-908.	0.6	12
150	Limited benefit of pentostatin salvage therapy for steroidâ€refractory grade <scp>III</scp>â€<scp>IV</scp> acute graftâ€versusâ€host disease. Clinical Transplantation, 2013, 27, 930-937.	0.8	11
151	Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e151-e156.	0.2	11
152	Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e73-e81.	0.2	11
153	Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System lowâ€, intermediateâ€1â€, intermediateâ€2â€, and highâ€risk myelofibrosis in JUMP, a Phase 3b, expandedâ€access study. Hematological Oncology, 2021, 39, 558-566.	0.8	11
154	Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I. Blood, 2012, 120, 1733-1733.	0.6	11
155	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 1908-1918.	1.3	10
156	Enasidenib in Combination with Venetoclax in IDH2-Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial. Blood, 2021, 138, 1263-1263.	0.6	10
157	The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Advances, 2022, 6, 1162-1174.	2.5	10
158	Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada. Leukemia and Lymphoma, 2020, 61, 1908-1919.	0.6	9
159	Momelotinib reduces transfusion requirements in patients with myelofibrosis. Leukemia and Lymphoma, 2022, 63, 1718-1722.	0.6	8
160	Superstition but not distrust in the medical system predicts the use of complementary and alternative medicine in a group of patients with acute leukemia. Leukemia and Lymphoma, 2008, 49, 339-341.	0.6	7
161	High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission. Leukemia Research, 2013, 37, 556-560.	0.4	7
162	Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 715-727.	0.2	7

#	Article	IF	Citations
163	AML refractory to primary induction with Ida-FLAG has a poor clinical outcome. Leukemia Research, 2018, 68, 22-28.	0.4	7
164	Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. Blood Advances, 2020, 4, 3063-3071.	2.5	7
165	Management of Hyperleukocytosis in Acute Myelogenous Leukemia Using Hydroxyurea Rather Than Leukopheresis.. Blood, 2006, 108, 2007-2007.	0.6	7
166	Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?. Hematology American Society of Hematology Education Program, 2021, 2021, 453-462.	0.9	7
167	HLA-Matched Sibling Transplantation for Severe Aplastic Anemia: Impact of HLA DR15 Antigen Status on Engraftment, Graft-versus-Host Disease, and Overall Survival. Biology of Blood and Marrow Transplantation, 2012, 18, 1401-1406.	2.0	6
168	Birth Order and Transplantation Outcome in HLA-Identical Sibling Stem Cell Transplantation: An Analysis on Behalf ofÂthe Center for International Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 741-745.	2.0	6
169	Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen. Leukemia Research, 2014, 38, 532-536.	0.4	6
170	Establishing an autologous versus allogeneic hematopoietic cell transplant program in nations with emerging economies. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 173-177.	0.6	6
171	Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 774-781.	0.2	6
172	A case of secondary acute myeloid leukemia on a background of glycogen storage disease with chronic neutropenia treated with granulocyte colony stimulating factor. JIMD Reports, 2019, 49, 37-42.	0.7	6
173	Application of Stem Cell Therapy in Myelofibrosis. Hematology/Oncology Clinics of North America, 2021, 35, 391-407.	0.9	6
174	Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study. British Journal of Haematology, 2021, 194, 557-567.	1.2	6
175	Trisomy 4 as the sole cytogenetic abnormality in a patient with T-cell acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2004, 152, 158-162.	1.0	5
176	Alternative donor transplants for high-risk acute myeloid leukemia. Current Opinion in Hematology, 2008, 15, 115-120.	1.2	5
177	Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis. Transplantation and Cellular Therapy, 2021, 27, 600.e1-600.e8.	0.6	5
178	Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,. Blood, 2011, 118, 3842-3842.	0.6	5
179	Natural killer-like T-cell leukaemia/lymphoma. British Journal of Haematology, 2001, 115, 490-490.	1.2	4
180	Risk of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients with myeloproliferative neoplasms treated with ruxolitinib. Leukemia and Lymphoma, 2021, 62, 495-497.	0.6	4

#	Article	IF	Citations
181	Shared-care model for complex chronic haematological malignancies. Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique, 2021, 31, 165-174.	0.1	4
182	Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience. Blood, 2020, 136, 33-34.	0.6	4
183	Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort. Leukemia, 2022, 36, 1689-1692.	3.3	4
184	Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment <scp>(COMFORT)â€Ł</scp> study. British Journal of Haematology, 2022, 198, 1065-1068.	1.2	4
185	Cavernous sinus thrombosis presenting with diplopia in an allogeneic bone marrow transplant recipient. American Journal of Hematology, 2004, 77, 77-81.	2.0	3
186	Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. Leukemia and Lymphoma, 2005, 46, 525-531.	0.6	3
187	Relationship Between Ruxolitinib Dose and Improvements in Spleen Volume and Symptoms in Patients With Myelofibrosis: Results From COMFORT-I. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S371-S372.	0.2	3
188	Controversies and dilemmas in allogeneic transplantation for myelofibrosis. Best Practice and Research in Clinical Haematology, 2014, 27, 165-174.	0.7	3
189	A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. Supportive Care in Cancer, 2019, 27, 2295-2300.	1.0	3
190	Impact of Genetic Mutations on the Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia with Antecedent Myeloproliferative Neoplasm. Biology of Blood and Marrow Transplantation, 2020, 26, S12.	2.0	3
191	Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.. Journal of Clinical Oncology, 2012, 30, 6624-6624.	0.8	3
192	Emerging therapeutic options for myelofibrosis: a Canadian perspective. American Journal of Blood Research, 2012, 2, 170-86.	0.6	3
193	CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study. Blood, 2020, 136, 6-7.	0.6	3
194	Acute Promyelocytic Leukemia: A Case-based Review. Hematology, 2003, 8, 105-113.	0.7	2
195	Acquired aplastic anemia and Fanconi anemia. , 2009, , 165-176.		2
196	Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBFâ€AML) â€“ a single center analysis. Hematological Oncology, 2017, 35, 810-813.	0.8	2
197	Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived. Leukemia and Lymphoma, 2018, 59, 237-240.	0.6	2
198	Management of Polycythemia Vera: A Survey of Canadian Physician Practice Patterns. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e37-e42.	0.2	2

#	Article	IF	Citations
199	Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series. Leukemia and Lymphoma, 2021, 62, 1525-1527.	0.6	2
200	Effect of preâ€transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. European Journal of Haematology, 2021, 107, 517-528.	1.1	2
201	Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS. Blood, 2020, 136, 1-2.	0.6	2
202	Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis. Blood, 2011, 118, 1750-1750.	0.6	2
203	Clinical Relevance of Cytogenetics Abnormalities in Adult Patients with Acquired Aplastic Anaemia.. Blood, 2005, 106, 3748-3748.	0.6	2
204	Management of Cytopenias With Ruxolitinib Treatment in Patients With Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S371.	0.2	1
205	Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response. Leukemia and Lymphoma, 2014, 55, 2398-2401.	0.6	1
206	Myelofibrosisâ€"When Do We Select Transplantation or Non-transplantation Therapeutic Options?. Current Hematologic Malignancy Reports, 2016, 11, 6-11.	1.2	1
207	Buried Barrett's Adenocarcinoma Clearly Demonstrated with Acetic Acid Chromoendoscopy. American Journal of Gastroenterology, 2018, 113, 1580.	0.2	1
208	Feasibility of Outpatient Consolidation Chemotherapy and Toxicity in Elderly Patients with AML.. Blood, 2009, 114, 1036-1036.	0.6	1
209	Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I). Blood, 2011, 118, 5146-5146.	0.6	1
210	Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.. Journal of Clinical Oncology, 2016, 34, 7012-7012.	0.8	1
211	Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen. Current Oncology, 2021, 28, 128-137.	0.9	1
212	Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era. Blood, 2020, 136, 52-53.	0.6	1
213	Hematopoietic cell transplantation for myelofibrosis: who and when?. , 0, , 86-96.		0
214	Hematopoietic Cell Transplantation for Myeloproliferative Neoplasms. , 2019, , 173-183.		0
215	Hydroxycarbamideâ€related cutaneous ulcer complicated byÂosteomyelitis. EJHaem, 0, , .	0.4	0
216	Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset of Chronic Gvhd. Blood, 2012, 120, 4184-4184.	0.6	0

#	Article	IF	Citations
217	High-Dose Cytarabine-Based Consolidation Shows Superior Results for Elderly AML Patients with Intermediate Risk Cytogenetics in First Complete Remission. Blood, 2012, 120, 3574-3574.	0.6	0
218	Comparison of the Impact of Two Different Definitions of Red-Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF). Blood, 2014, 124, 3180-3180.	0.6	0
219	Myelofibrosis Is Initiated and Sustained By Rare Multipotent Stem Cells. Blood, 2018, 132, 1790-1790.	0.6	0
220	HSCs Fated to Progress to Blast Phase Can be Detected in Myelofibrosis Patients Several Years Prior to Leukemic Transformation. Blood, 2019, 134, 1676-1676.	0.6	0
221	Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA. Blood, 2020, 136, 35-36.	0.6	0
222	Geographical Distance from Quaternary Treatment Center Does Not Impact Choice of Upfront Therapy, Clinical Trial Participation and Outcomes in Patients with Newly Diagnosed AML. Blood, 2020, 136, 15-16.	0.6	0
223	Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Harboring DNMT3A/TET2/ASXL1 Mutation. Blood, 2020, 136, 8-9.	0.6	0
224	Clinical Significance of Emergent Leukocytosis in Patients with Myelofibrosis Receiving JAK Inhibitor Therapy. Blood, 2020, 136, 22-22.	0.6	0